Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) COO Sells 7,886 Shares of Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) COO Azmi Nabulsi sold 7,886 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total transaction of $51,968.74. Following the completion of the transaction, the chief operating officer now owns 233,390 shares in the company, valued at approximately $1,538,040.10. This represents a 3.27 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Azmi Nabulsi also recently made the following trade(s):

• On Thursday, December 19th, Azmi Nabulsi sold 1,118 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $8.00, for a total transaction of $8,944.00.

Phathom Pharmaceuticals Price Performance

Shares of NASDAQ:PHAT traded up $0.18 during trading on Thursday, hitting $7.17. The company’s stock had a trading volume of 649,136 shares, compared to its average volume of 943,045. The company has a 50-day moving average of $8.08 and a 200-day moving average of $12.53. The firm has a market cap of $490.28 million, a price-to-earnings ratio of -1.26 and a beta of 0.56. Phathom Pharmaceuticals, Inc. has a 12 month low of $6.07 and a 12 month high of $19.71.

Phathom Pharmaceuticals (NASDAQ:PHAT) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.32) earnings per share for the quarter, topping the consensus estimate of ($1.57) by $0.25. The business had revenue of $16.35 million during the quarter, compared to the consensus estimate of $12.54 million. During the same quarter in the previous year, the business posted ($0.76) earnings per share. As a group, research analysts anticipate that Phathom Pharmaceuticals, Inc. will post -4.74 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Needham & Company LLC reissued a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a research note on Thursday, December 12th.

Hedge Funds Weigh In On Phathom Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of PHAT. Jennison Associates LLC increased its position in Phathom Pharmaceuticals by 112.7% in the third quarter. Jennison Associates LLC now owns 5,866,389 shares of the company’s stock worth $106,064,000 after buying an additional 3,108,810 shares in the last quarter. Portolan Capital Management LLC raised its stake in Phathom Pharmaceuticals by 50.4% during the 3rd quarter. Portolan Capital Management LLC now owns 1,699,918 shares of the company’s stock worth $30,735,000 after acquiring an additional 569,829 shares during the period. Checkpoint Capital L.P. lifted its holdings in Phathom Pharmaceuticals by 71.9% during the third quarter. Checkpoint Capital L.P. now owns 1,504,307 shares of the company’s stock valued at $27,198,000 after purchasing an additional 629,307 shares in the last quarter. FMR LLC boosted its position in shares of Phathom Pharmaceuticals by 49,000.7% in the third quarter. FMR LLC now owns 1,304,114 shares of the company’s stock worth $23,578,000 after purchasing an additional 1,301,458 shares during the period. Finally, State Street Corp increased its stake in shares of Phathom Pharmaceuticals by 17.5% in the third quarter. State Street Corp now owns 922,788 shares of the company’s stock worth $16,684,000 after purchasing an additional 137,539 shares in the last quarter. 99.01% of the stock is currently owned by hedge funds and other institutional investors.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.